

NEWS RELEASE

NEWS RELEASE

NEWS RELEASE

CONTACT FOR MORE INFORMATION:

Mike Williams, EVP
(844) 545-4508 ext. 402

FOR IMMEDIATE RELEASE – December 6, 2016

**MEMREG, INC. ANNOUNCES THE FORMAL RENEWAL OF THE
SPECIAL EXERCISE PRICE PROGRAM FOR ALL SERIES OF WARRANTS**

Phoenix, Arizona, December 6, 2016 -- (OTC Markets News Service). MemReg, Inc. (OTC:MREG) (the “Company”) announced today that it renewed the temporary reduction of the exercise price for all its outstanding warrants to \$.3333 (“Special Exercise Price”) until 5:00 pm, MST on Friday, December 29, 2016. On December 29, 2016, the Company may extend this Special Exercise Price for up to an additional sixty days. The Special Exercise Price was originally announced on July 8, 2016 for all Warrant Series, but expired on October 6, 2016, except with respect to the Series B Warrants. The expiration of the Special Exercise Price for the Series B Warrants had been extended until December 5, 2016, but is now formally reset by this latest extension.

There are currently approximately 38,000,000 warrants of all Series outstanding. At the expiration of the Special Exercise Price, the Series B Warrants revert to a \$2.00 exercise price, the Series C&D Warrants revert to a \$3.00 exercise price and the Series E&F Warrants revert to a \$4.00 exercise price. The Warrants all expire on December 31, 2016 but will be renewed for a term yet to be determined.

The determination to renew the Special Exercise Price for all Warrant Series is intended to:

- Alleviate confusion among warrant holders resulting from applying the Special Exercise Price to only the B Series Warrants;
- Allow all warrant holders in addition to the B Series Warrant holders to exercise their warrants at the Special Exercise Price;
- Reduce the Warrant exercise price to more closely correspond to the value of the Company’s stock as negotiated in the ORhub asset acquisition transaction, which is intended to allow warrant holders to reduce dilution resulting from the ORhub transaction on terms similar to the ORhub transaction, and
- Raise capital for the Company’s operations and expansion of its ORhub business.

The terms of the warrants restrict the number of warrants that can be exercised by a holder to an amount that would cause such holder’s ownership of the Company’s stock to be no greater than 4.99% of all outstanding shares after such exercise. In the past, the Company has increased the beneficial ownership limitation on exercise of additional warrants from 4.99% to 9.99% upon request and undertaking of such holder to supply ongoing information to satisfy the Company’s reporting requirements. In the past, six holders have requested and agreed to these requirements and a new holder has just asked for a waiver.

About the Company. On June, 30, 2016, the Company acquired all the assets of ORhub, LLC (“ORhub”). The assets acquired included the ORhub software, a platform for the tracking and management of medical devices and supplies, primarily in implant orthopedic surgeries. The Company is initially focusing on spinal implant surgeries. On October 6, 2016, the Company announced its production version was being used exclusively by a major regional hospital in California. The Company estimates that annually there are 7,000,000 implant based orthopedic and other surgeries that could use the ORhub platform and that this number is growing at 6% a year. The Company’s mission is to create a new healthcare IT vertical-specific software category known as Surgical Resource Management. The Company believes it can create, as a byproduct of immediately realized productivity benefits, the world’s largest source of intelligent surgical information – a suite of products to better serve the needs of the healthcare industry, patients, and the government. The ORhub product is anticipated to enable hospital and vendor cost reductions, enhance accountability, automate implant registries, create real-time advanced analytics, and improve compliance with insurance and government requirements.

More information on the Company’s business, product and the management team can be found on the Company’s website at www.orhub.com. The Company currently trades on the Pink Sheets-Current Information Tier under the symbol MREG. Information on the Company, including unaudited financial information is available at OTC Markets under the symbol MREG.

MemReg’s office is located at 9830 S. 51st Street, Suite A-128, Phoenix, AZ 85044. The Company expects to continue to publish and post its financial information for investors on its web site.

Forward Looking Statements. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurances that its expectations will be attained. Such statements are inherently uncertain, and actual results and activities may differ materially from those estimated or projected. Certain factors that can affect the Company’s ability to achieve its anticipated results include, among others, uncertainties inherent in the development of a new software product business.

#